Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

Inclusion Criteria

• •Aged 18-70 years old (including 18 and 70 years old) with newly diagnosed favorable-risk AML (2022 ELN risk group classification).
• •Achieved CR1 after 1-2 cycles of standard chemotherapy.
• •Completed 4-6 cycles of consolidation chemotherapy (including at least 2 cycles of high-dose Cytarabine HDAC regimem).
• •At the end of consolidation treatment, bone marrow examination confirmed in CR1, flow cytometry MRD negative, but molecular MRD genes (RUNX1:: RUNX1T1, NPM1, and CBFb:: MYH11) decreased by \> 3 log, but still detectable.
• •Performance status score of 0-2 (ECOG).
• •Liver function: ALT and AST ≤ 2.5 times the upper limit of normal, bilirubin ≤ 2 times the upper limit of normal.
• •Kidney function: Creatinine ≤ 1.5 times the upper limit of normal.